key: cord-1016430-zbot25jf
authors: Hauguel-Moreau, Marie; Hajjam, Mostafa El; De Baynast, Quentin; Vieillard-Baron, Antoine; Lot, Anne-Sophie; Chinet, Thierry; Mustafic, Hazrije; Bégué, Céline; Carlier, Robert Yves; Geri, Guillaume; Dubourg, Olivier; Beaune, Sébastien; Mansencal, Nicolas
title: Occurrence of pulmonary embolism related to COVID-19
date: 2020-10-06
journal: J Thromb Thrombolysis
DOI: 10.1007/s11239-020-02292-4
sha: 03a66d819042de443eadfd11cdf838d53ef48460
doc_id: 1016430
cord_uid: zbot25jf

Recent reports have suggested an increased risk of pulmonary embolism (PE) related to COVID-19. The aim of this cohort study is to compare the incidence of PE during a 3-year period and to assess the characteristics of PE in COVID-19. We studied consecutive patients presenting with PE (January 2017–April 2020). Clinical presentation, computed tomography (CT) and biological markers were systematically assessed. We recorded the global number of hospitalizations during the COVID-19 pandemic and during the same period in 2018-2019. We included 347 patients: 326 without COVID-19 and 21 with COVID-19. Patients with COVID-19 experienced more likely dyspnea (p=0.04), had lower arterial oxygen saturation (p<0.001), higher C-reactive protein and white blood cell (WBC) count (p<0.0001 and p=0.001, respectively), and a significantly higher in-hospital mortality (14% versus 3.4%, p=0.04). Among COVID-19 patients, diagnosis of PE was performed at admission in 38% (n=8). COVID-19 patients with diagnosis of PE during hospitalization (n=13) had significantly more dyspnea (p=0.04), lower arterial oxygen saturation (p=0.01), less proximal PE (p=0.02), and higher heart rate (p=0.009), CT severity score (p=0.001), C-reactive protein (p=0.006) and WBC count (p=0.04). During the COVID-19 outbreak, a 97.4% increase of PE incidence was observed as compared to 2017–2019 and the proportion of hospitalizations related to PE was 3.7% versus 1.3% in 2018–2019 (p<0.0001). In conclusion, the COVID-19 pandemic leads to a dramatic increased incidence of PE. Physicians should be aware that PE may be diagnosed at admission, but also after several days of hospitalization, with a different clinical, CT and biological features of thrombotic disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11239-020-02292-4) contains supplementary material, which is available to authorized users.

All our health care systems have been recently impacted by the emergence of the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] . This new disease, COVID-19, exhibits various clinical presentations [2, 3] . One of the concerns of COVID-19 is the increased thrombotic risk, resulting in pulmonary embolism (PE) [4] [5] [6] [7] [8] [9] . However, little is known about the characteristics of patients presenting with PE and COVID- 19 . The aim of the study was to compare the incidence of PE during a 3-year period (including COVID-19 outbreak) and to assess the characteristics of PE in COVID-19.

Between March 2nd and April 30th 2020, all patients referred for pulmonary computed tomography (CT) in our university hospital with a PE diagnosis were prospectively included. There was no exclusion criterion. A search for COVID-19 was systematically performed, using a polymerase-chain-reaction (PCR) and/or typical CT pattern of SARS-CoV-2 [10, 11] . Treatment and management was left to physicians'discretion, according to current guidelines [10] . A historical cohort of PE included all consecutive patients referred for PE at our university hospital between January 1st, 2017 and March 1st, 2020. We identified patients presenting with PE using the International Classification of Diseases version 10 until the COVID-19 outbreak (I260 and I269 codes). We systematically reviewed all clinical parameters, electrocardiogram (ECG), computed tomography (CT), echocardiography and biomarkers. We compared the characteristics of PE in patients presenting with COVID-19 with the characteristics of PE diagnosed between 2017 and 2020 in patients without COVID-19. The study was approved by the Institutional Data Protection Authority of Paris Saclay University Hospitals.

Diagnosis of PE was performed by pulmonary CT angiography, using a 256 slice multi-detector CT (GE Healthcare Revolution, Milwaukee, WI). Multi-detector chest CT angiography was performed after intravenous injection of 50 ml iodinated contrast agent (Iomeron 400 mg I/mL, Bracco Imaging, Milan, Italy) at a flow rate of 3.5 mL/s, with a trigger positioned on the main pulmonary artery. CT parameters were 120 kVp, average tube current 300 mA, 80 x 0.625 mm, rotation time 0.28 s, pitch 0.992 and CTDI vol of 4.28 mGy. Chest CT is a cornerstone of the diagnostic work-up and follow-up for patients with COVID-19. Both features COVID-19 lung involvement and PE were prospectively analyzed on a PACS workstation (Carestream Health, Rochester, NY) by an experienced radiologist blinded to clinical and biological data. The degree of lung involvement by SARS-CoV-2 was assessed for each lobe and classified as none (0%), minimal (1%-25%), mild (26%-50%), moderate (51%-75%), or severe (76%-100%). For each lobe, no involvement corresponded to a score of 0, minimal involvement to a score of 1, mild involvement to a score of 2, moderate involvement to a score of 3, and severe involvement to a score of 4. An overall lung "total severity score" was reached by summing the five lobe scores (range of possible scores, 0-20) [11, 12] .

Pulmonary embolism was diagnosed if an endoluminal thrombus was present in a normal-sized or enlarged vessel. The location of PE, i.e., the site of the largest thrombus, was noted. Assessment of right ventricular size was performed by CT and echocardiography. Right ventricular size was systematically assessed using a CT four-chamber view passing through the mitral and tricuspid valves. We calculated the right to left ventricular area ratio and a right ventricular dilation was defined as a right to left ventricular area ratio >1 [13] . Echocardiographic examinations were performed using a Vivid 9, Vivid E95 or S70 system (GE Medical Systems, Horten, Norway). In an apical four-chamber view, a right ventricular dilation was defined as a right to left ventricular area ratio >0.6 [10] . Clinical presentation, simplified version of pulmonary embolism severity index (sPESI) [13, 14] , ECG, location of pulmonary embolism by CT, right ventricular size by CT and by echocardiography, troponin I, D-dimers, plasma N-terminal-pro B-natriuretic peptide concentration (proBNP) and classification of PE severity (high-risk, intermediate [-high or -low] risk and low risk PE) [10] were systematically assessed. Finally, we recorded the global number of hospitalizations during the COVID-19 pandemic and during the same period in 2018 and 2019 and the number of patients presenting with COVID-19.

Statistical analysis was performed using StatView software version 4.5 (Abacus Concepts, Berkeley, CA). Continuous variables are presented as mean ± SD (standard deviation) and categorical data are presented as absolute values and percentages. Continuous and categorical variables were compared using the chi-square test or Fisher's exact test and unpaired t test, respectively. Missing data were addressed by listwise deletion. A value of p < 0.05 was considered statistically significant.

We included 347 patients presenting with PE: 326 without COVID-19 and 21 patients with COVID-19. The characteristics of our population are presented in Table 1 . Patients with PE and COVID-19 were significantly more likely to experience dyspnea (p = 0.04), presented with lower arterial oxygen saturation (p < 0.001), higher C-reactive protein and white blood cell (WBC) count (p < 0.0001 and p = 0.001, respectively), and a significantly higher in-hospital mortality (p = 0.04). No patient with PE and COVID-19 had normal D-dimers, but three patients (14%) had D-dimers lower than 2500 ng/mL (versus 121 patients [37%] in patients with PE without COVID-19 [p = 0.04]). The prevalence of proximal PE was significantly higher in patients without COVID-19 (40% versus 14%, p = 0.02).

Among patients with COVID-19, pulmonary embolism was diagnosed at admission in only 38% (n = 8) with a clinical presentation of PE. In the remaining patients with COVID-19 (n = 13), diagnosis of PE was performed at day 8.5 ± 6.3 of hospitalization, because of worsening of symptoms (acute degradation of hemodynamic or respiratory status) ( Table 2 ). All of these patients received a prophylactic anticoagulant treatment (Supplementary Table 1 ). The initial diagnosis of admission was SARS-CoV-2 pneumonia without PE. In comparison with COVID-19 with a diagnosis of PE at admission, patients who were diagnosed PE during hospitalization had a higher rate of dyspnea (p = 0.04), a higher heart rate (p = 0.009), lower arterial oxygen saturation (p = 0.01), higher C-reactive protein and WBC count (p = 0.006 and p = 0.04, respectively), a higher sPESI (p = 0.006) and a higher SARS-CoV-2 severity CT score (p = 0.001). Pulmonary embolism without proximal location ( Fig. 1 ) was significantly more frequent in patients developing PE during hospitalization (p = 0.02).

Clinical and biological characteristics of COVID-19 patients with PE at admission and non COVID-19 patients were similar, except for arterial oxygen saturation (p = 0.03) (Tables 1 and 2 ). Heart rate, C-reactive protein, WBC count were significantly higher in COVID-19 patients with PE diagnosed during hospitalization as compared to patients without COVID-19 (105 bpm versus 91 bpm, p = 0.04, 157 versus 50 mg/L, p < 0.0001, 14,430 versus 9672 x10*9/L , p < 0.001, respectively) and arterial oxygen saturation was significantly lower (75% versus 95%, p < 0.0001). Figure 2 shows the evolution of number of patients presenting with PE between 2017 and 2020. As compared to previous years, we found a significant increase of admissions for PE during the COVID-19 pandemic (increase of 97. 

The present study demonstrates an increased incidence of PE during COVID-19 pandemic. Interestingly, we found two patterns of patients presenting with PE and COVID-19 with significant differences: patients with PE at admission and patients with PE diagnosed during hospital stay.

Several studies have recently alerted on the frequent occurrence of venous thromboembolic disease in patients with COVID-19 [4, 9] . We found consistent results in our university hospital, with a 2.85-fold increase of PE hospitalizations. Pulmonary embolism is a well-known thromboembolic disease. Several predisposing factors have been widely published, such as previous PE, surgery, cancer, oral contraceptive therapy and immobilization [10] . To explain the increase in PE incidence during COVID-19 outbreak, several causes have been suggested. One could be that patients suffering from COVID-19 may be bedridden. In our study, 38% of patients with COVID-19 had a diagnosis of PE at admission. Interestingly, characteristics of these patients were similar to those of PE patients without COVID-19, suggesting a same thromboembolic process, with a predisposing factor related to immobilization. On the other hand, we individualized another group of patients with PE and COVID-19: patients developing PE during hospitalization. Those patients presented several clinical, biological and radiological differences, as compared to patients with PE without COVID-19 and to patients with COVID-19 and PE diagnosis at admission: important inflammatory syndrome, more severe pulmonary pattern of COVID-19, more dyspnea, increased heart rate, lower arterial oxygen saturation and less proximal PE. This finding suggests that the delayed occurrence of PE in some patients [3, 15] . This raises the hypothesis of intrapulmonary thrombosis related to COVID-19 during the cytokine storm syndrome [16] [17] [18] [19] [20] [21] . Potential limitations of the present study merit consideration. First, we recruited a limited number of patients presenting with PE and COVID-19, leading to non-significant In conclusion, the COVID-19 pandemic leads to a dramatic increased incidence in PE admissions. Physicians should be aware that PE may be diagnosed at admission, but also after several days of hospitalization, with a different pattern of thrombotic disease.

Pneumonia of unknown cause -China: disease outbreak news. Geneva: World Health Organization

Feng Z (2020) Early transmission dynamics in

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Lille ICU Haemostasis COVID-19 Group (2020) Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

CT imaging features of 2019 novel coronavirus (2019-nCoV)

CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)

Diagnosis of right ventricular dysfunction in acute pulmonary embolism using helical computed tomography

Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism

Large-vessel stroke as a presenting feature of Covid-19 in the young

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?

SARS-CoV-2: a storm is raging

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Coronavirus blood-clot mystery intensifies

Critical Covid-19 France Investigators (2020) Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec COVID-19 et surveillance de l'hémostase

The authors declare that they have no conflict of interest.